Hui Zhan (Nevada Institute of Personalized Medicine) has published a research article titled “Biomarker Identification for Alzheimer’s Disease Through Integration of Comprehensive Mendelian Randomization and Proteomics Data” in the Journal of Translational Medicine on March 6.

The study is co-authored by Dr. Jeffrey L. Cummings (Brain Health, Medicine), Dr. Xianjun Dong from Yale University, and Davis Cammann (Life Sciences).

This study utilizes comprehensive Mendelian randomization to identify causal proteins and genes associated with Alzheimer’s disease. By integrating large-scale genome-wide association studies, protein quantitative trait loci, and gene expression quantitative trait loci data, the research prioritizes five plasma proteins as potential biomarkers or drug targets for Alzheimer’s disease in European ancestry populations. These findings provide critical insights into AD pathology and may help guide future therapeutic development.

Zhan is Ph.D. student under Dr. Jingchun Chen (Nevada Institute of Personalized Medicine).